IL304895A - INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment - Google Patents

INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment

Info

Publication number
IL304895A
IL304895A IL304895A IL30489523A IL304895A IL 304895 A IL304895 A IL 304895A IL 304895 A IL304895 A IL 304895A IL 30489523 A IL30489523 A IL 30489523A IL 304895 A IL304895 A IL 304895A
Authority
IL
Israel
Prior art keywords
compound
morpholino
methyl
oxo
alkyl
Prior art date
Application number
IL304895A
Other languages
English (en)
Hebrew (he)
Inventor
Zhao Jean
Wang Qi
Y Yu Xiang
Cheng Huimin
Zhang Peiyu
Lin Zhixiong
Fang Lei
Ma Songling
Original Assignee
Geode Therapeutics Inc
Xtalpi Inc
Zhao Jean
Wang Qi
Y Yu Xiang
Cheng Huimin
Zhang Peiyu
Lin Zhixiong
Fang Lei
Ma Songling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geode Therapeutics Inc, Xtalpi Inc, Zhao Jean, Wang Qi, Y Yu Xiang, Cheng Huimin, Zhang Peiyu, Lin Zhixiong, Fang Lei, Ma Songling filed Critical Geode Therapeutics Inc
Publication of IL304895A publication Critical patent/IL304895A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL304895A 2021-02-01 2022-01-25 INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment IL304895A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144287P 2021-02-01 2021-02-01
PCT/US2022/013725 WO2022164812A1 (en) 2021-02-01 2022-01-25 Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof

Publications (1)

Publication Number Publication Date
IL304895A true IL304895A (en) 2023-10-01

Family

ID=82654889

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304895A IL304895A (en) 2021-02-01 2022-01-25 INHIBITORS OF PHOSPHOINOSITIDE 3 KINASE BETA Preparations containing them and their use for treatment

Country Status (9)

Country Link
US (1) US20240166617A1 (cg-RX-API-DMAC7.html)
EP (1) EP4284375A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024508045A (cg-RX-API-DMAC7.html)
KR (1) KR20240016938A (cg-RX-API-DMAC7.html)
CN (1) CN117615763A (cg-RX-API-DMAC7.html)
AU (1) AU2022214080A1 (cg-RX-API-DMAC7.html)
CA (1) CA3209581A1 (cg-RX-API-DMAC7.html)
IL (1) IL304895A (cg-RX-API-DMAC7.html)
WO (1) WO2022164812A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
MX2023013987A (es) 2021-05-27 2024-02-12 Petra Pharma Corp Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
TW202329930A (zh) 2021-09-30 2023-08-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之異位色烯酮抑制劑
US20260130925A1 (en) * 2022-10-14 2026-05-14 Genesis Molecular Ai, Inc. Methods for treating cancer
EP4602043A1 (en) * 2022-10-14 2025-08-20 Genesis Therapeutics, Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer
EP4680612A1 (en) * 2023-03-15 2026-01-21 AN2 Therapeutics, Inc. Chemical compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE363471T1 (de) * 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
EP1537102A4 (en) * 2002-08-16 2010-12-08 Astrazeneca Ab INHIBITORS OF PHOSPHOINOSITIDE-3-KINASE BETA
WO2008148074A2 (en) * 2007-05-24 2008-12-04 Research Foundation Of State University Of New York Inhibitors of mtor and methods of treatment using same
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives

Also Published As

Publication number Publication date
WO2022164812A1 (en) 2022-08-04
US20240166617A1 (en) 2024-05-23
CA3209581A1 (en) 2022-08-04
AU2022214080A1 (en) 2023-09-14
EP4284375A1 (en) 2023-12-06
CN117615763A (zh) 2024-02-27
KR20240016938A (ko) 2024-02-06
JP2024508045A (ja) 2024-02-21
EP4284375A4 (en) 2025-04-23

Similar Documents

Publication Publication Date Title
TW202144345A (zh) Kras突變蛋白抑制劑
RU2719477C2 (ru) Соединение, ингибирующее brk
TW202328124A (zh) 1,4-氧雜氮雜環庚烷衍生物及其用途
US20240166617A1 (en) Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
JP5766820B2 (ja) Pi3キナーゼ阻害剤としての複素環化合物
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
TW202128691A (zh) Kras 突變蛋白抑制劑
CN114072409B (zh) 炔类衍生物及其制备方法和用途
ES2339174T3 (es) N-(aril- o heteroaril)-pirazo(1,5-a)pirimidinas 3-sustituidas como inhibidores de cinasa.
CN113527335A (zh) 作为egfr抑制剂的大环类化合物及其应用
TW201213324A (en) Fused heterocyclic compounds
AU2011288876A2 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
ES2978573T3 (es) Compuestos antibacterianos
CN105452257A (zh) 新型稠合嘧啶化合物或其盐
CN108349996A (zh) 三环pi3k抑制剂化合物及其使用方法
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
CN113234072A (zh) Fgfr4抑制剂、其制备方法和应用
WO2024173453A1 (en) Heteroaryl-substituted imidazopyridine compounds
CN120574242A (zh) 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
WO2023078451A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN108191837A (zh) PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
CN121758446A (zh) 咪唑酮类化合物及其制备方法和应用
TW202610649A (zh) 氮雜并環類衍生物及其製備方法和用途
CN114599655B (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3259052A1 (en) HETEROCYCLIC COMPOUNDS USED AS PI3K.ALPHA INHIBITORS.